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Abstract
Background: In the UK, there is ongoing integration of pharmacists into general practice as a new healthcare service
in primary care. Evaluation of the service involves national measures that require pharmacists to record their work, on
the general practice clinical computer systems, using electronic activity codes. No national agreement, however, has
been established on what activities to record. The purpose of this study was to attempt to reach consensus on what
activities general practice-based pharmacists should record.
Methods: The e-Delphi method was chosen as it is an excellent technique for achieving consensus. The study began
with an initial stage in which screening of a general practice clinical computer system and discussion groups with
pharmacists from two ‘pharmacists in general practice’ sites identified 81 codes potentially relevant to general practice-
based pharmacists’ work. Twenty-nine experts (pharmacists and pharmacy technicians from the two sites along with
experts recruited through national committees) were then invited by e-mail to participate as a panel in three e-Delphi
questionnaire rounds. In each round, panellists were asked to grade or rank codes and justify their choices. In every
round, panellists were provided with anonymised feedback from the previous round which included their individual
choices along with their co-panellists’ views. Final consensus (in Round 3) was defined as at least 80% agreement.
Commentaries on the codes from all e-Delphi rounds were pooled together and analysed thematically.
Results: Twenty-one individual panellists took part in the study (there were 12 responses in Round 1, 18 in Round 2
and 16 in Round 3). Commentaries on the codes included three themes: challenges and facilitators; level of detail; and
activities related to funding. Consensus was achieved for ten codes, eight of which related to activities (general and
disease specific medication reviews, monitoring of high-risk drugs and medicines reconciliation) and two to patient
outcomes (presence of side effects and satisfactory understanding of medication).
Conclusions: A formal consensus method revealed general practice-based pharmacists’ preferences for activity coding.
Findings will inform policy so that any future shaping of activity coding for general practice-based pharmacists takes
account of pharmacists’ actual needs and preferences.
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Background
In England, there is an ongoing drive to incorporate phar-
macists into general practice (known as ‘family practice’ in
some countries) which has been co-supported by the Na-
tional Health Service (NHS) England, Health Education
England, the Royal College of General Practitioners, the
British Medical Association’s General Practitioners Com-
mittee and the Royal Pharmaceutical Society. In 2015, a
national pilot scheme was introduced that partially cov-
ered the expenses of co-locating pharmacists into general
practices as equal members in the multidisciplinary teams
[1]. An amount of £31 million was invested in the pilot
which formed a component of a wider plan [2] aiming to
address needs in the primary care workforce (i.e. a short-
age of roughly 8000 general practitioners (GPs) and, by
2040, an oversupply of 11,000 to 19,000 newly qualified
pharmacists [3]). The pilot led to approximately 490 new
general practice-based pharmacists’ posts across 90 sites
which included approximately 658 general practices [4]. A
pilot site, now ‘pharmacists in general practice’ site, in-
cludes a number of general practices participating in the
pilot scheme as part of the same organisation. An example
of a pilot site is a GP Federation (i.e. a group of practices,
in the UK, working together within their geographical area
as part of a collective entity). Following the pilot, the num-
ber of general practice-based pharmacists has increased as
a result of a second roll-out phase [5]. The ultimate pur-
pose with this second phase has been to integrate an add-
itional 1500 pharmacists into general practices by 2020/21
thus having approximately one pharmacist per 30,000 pa-
tient population. The overall goal of the ‘pharmacists in
general practice’ scheme is to reduce the workload of
overburdened GPs (thus enabling them to manage their
time-demands and focus where they are most needed, for
example, diagnostics or treating patients with rare or very
complex conditions) and ease patients’ access to health-
care services and checks [6]. Integrating pharmacists into
general practice is also expanding to Wales, Scotland and
Northern Ireland [7–10].
Historically, the pharmacy profession has been striv-
ing, across the globe, to gain recognition of pharmacists’
clinical roles by other healthcare professions and the
public [11]. Every new clinical pharmacy service has
therefore needed to demonstrate its effectiveness, effi-
ciency and contribution to patient care to justify its ne-
cessity and continued funding [12, 13]. Internationally,
the greatest challenges when integrating pharmacists
into general practices have been overcoming GPs’ reluc-
tance to accept pharmacists’ clinical interventions [14,
15] and patients’ unfamiliarity with pharmacists’ roles in
this environment [16, 17]. To capture the impact of gen-
eral practice-based pharmacists, and thus show their
usefulness, a number of approaches have been employed
internationally. In Australia, for example, the number of
medication-related problems experienced by patients
(such as incorrect medication or dose, adverse drug re-
actions and interactions) was measured before and six
months after a consultation with a general practice-
based pharmacist [18]. Measurements were done by
interviewing patients and auditing their records. Results
showed significant reductions in medication-related
problems with pharmacists’ intervention. In Canada, a
postal questionnaire was sent to GPs (at the 3rd, 12th
and 19th month of pharmacists’ integration into general
practices) asking them to grade their own and pharma-
cists’ contributions to a number of general practice-
based activities [19]. Findings revealed the increasing
contributions of pharmacists to diagnosis, prescribing,
monitoring, medication reviews and education.
In the UK, NHS England has proposed a set of ten na-
tional Key Performance Indicators (KPIs) to evaluate the
impact of the introduction of general practice-based
pharmacists on patients, GPs and the wider healthcare
system [20]. Eight of the KPIs are based on numerical
components and two are survey-based (see Table 1). For
the numerical KPIs, UK general practice-based pharma-
cists are required to record their day-to-day work on the
Table 1 National Key Performance Indicators (KPIs)
Numerical KPIs
• Number of patient appointments with: General practitioner (GP),
Practice Nurse, Clinical Pharmacist, Health Care Assistant/Advanced
Nurse Practitioner
• Impact on the percentage of patients who met the achievement
indicator within the relevant Quality and Outcomes Framework-QOF
(increase in the average QOF score)
• Increase in total number of medication reviews
• Decrease in the percentage of medication reviews undertaken by
GPs
• Increase in the total number of patients supported to develop care
and support plans, including self-management
• The rate of Accident & Emergency attendances per 1000 patients on
GP register
• Rate of emergency hospital admissions for selected long-term
conditions as a proportion of patients per GP practice
• Reduction in the number of patients attending ≥15 appointments
with a GP over the previous two years by age group (0–9, 10–19, 20–
39, 40–59, 60–69, 70–89, 90+)
• Reduction in antibiotic prescribing rate (versus national rate per
STARPU*)
• Reduction in prescribing rate of anti-psychotic medications for
patients with dementia or learning disabilities
Survey-based KPIs
• Patient satisfaction survey (patient experience)
• GP survey (impact on workload, time, utilisation, job satisfaction)
*STARPU (Specific Therapeutic Group Age-sex weightings Related Prescribing
Units): a weighting system that takes into account the types of people
receiving treatment within a specific therapeutic group to compare drug use
between NHS organisations and practices
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clinical computer systems in the general practices by
using pre-existing, non-pharmacy specific, electronic
activity codes. SystmOne, EMIS and INPS Vision are the
main clinical record systems used in UK general prac-
tices. At the time of writing, there has been no national
agreement on what general practice-based pharmacists’
activities are worth capturing on a regular basis. A re-
cent paper (2019) found that UK general practices still
do not have a formal and/or common process for meas-
uring the impact of their pharmacists (practices infor-
mally looked for reductions in their GPs’ workload or
their improved performance in terms of quality inspec-
tions and national targets) [21]. A formal evaluation of
the initial pilot scheme, based on the opinions of health-
care staff and patients, reported benefits for the practices
(such as increased capacity, more focused workload for
GPs and reductions in costs) and patients (such as avail-
ability of longer appointments with the same person in
the practice) [22]. Although the evaluation looked at
pharmacists’ perceptions about their roles, it made no
quantitative measures of their activities. Moreover, a UK
qualitative study revealed that the current coding op-
tions are not tailored to pharmacists’ work (available
coding having pre-dated the ‘pharmacists in general
practice’ scheme) and concluded that they are not fit for
purpose to effectively identify the spectrum of pharma-
cists’ tasks within the general practice environment [23].
The purpose, therefore, of this study was to reach a
broad consensus amongst experts on what general prac-
tice-based pharmacists’ activities should be recorded on
the general practice clinical computer systems.
Methods
Study methodology
The Delphi method was selected for the current study
because it enables consensus amongst experts (panel-
lists) on a topic that lacks evidence [24–26]. The Delphi
method involves an initial stage in which the recruited
panel of experts identifies the spectrum of predominant
problems which are then transformed into statements
and ranked in a succession of consecutive questionnaire
rounds. In each round, responses are influenced by con-
trolled feedback from the previous round (i.e. panellists
are offered an anonymised summary of their counter-
parts’ views). The study completes when a pre-defined
agreement percentage is reached or after a pre-agreed
number of rounds [27].
Initial stage
Because there was no recent UK literature on pharma-
cists’ activities in general practice at the time of begin-
ning this study, two members of the research team (GS-
service lead and GDK-doctorate research student)
screened the largest general practice computer system
(SystmOne) and built up a list of 69 codes potentially
relevant to general practice-based pharmacists’ work.
The vast majority of codes were related to activities but
there were also a few codes concerning patient outcomes
that were included due to their potential high relevance
to pharmacists’ activities in this setting as determined by
GS. Face-to-face focus groups were then conducted with
general practice-based pharmacists (from two West
London sites) in which participants were asked to dis-
cuss which codes on the list might be useful and suggest
any other pharmacists’ activities worth considering as
coding options. These focus group discussions were
audio-recorded, transcribed verbatim and analysed the-
matically (for detail, see reference [23]). A further 12
codes were generated from the focus group discussions.
In total, a collection of 81 codes was assembled which
made up the questionnaire for Round 1 of the Delphi
study. An additional file presents all 81 codes (see Add-
itional file 1). Each code formed a different item in the
questionnaire. Two general practice-based pharmacists
and one pharmacy technician pilot tested the question-
naire for Round 1 and any modifications made there-
after. All questionnaires were created using the platform
of Online surveys (formerly known as Bristol Online
Surveys).
Expert panel
Clayton (1997) recommends 15 to 30 panellists as an
ideal size for Delphi panels [28]. Twenty-nine people
were identified as potential panel members for the
current study, using the following criteria: pharmacists
or pharmacy technicians working in general practice and
involved in coding general practice-based pharmacists’
activities either at a local or national level. Invitees
included all pharmacists and pharmacy technicians
working across two West London sites (at the time ap-
proximately 17 eligible staff members) along with other
national experts (12) holding senior general practice-
based pharmacists’ roles and widely engaged on national
committees. The West London sites were targeted for
recruitment because both have working connections
with the research team’s organisation (invitees from the
West London sites included most of the focus group
participants). The national experts were recruited
through the Centre for Pharmacy Postgraduate Educa-
tion and the Primary Care Pharmacy Association.
Recruitment process
Participation was voluntary and all 29 experts were in-
vited to participate in each round. All invitation e-mails
for Round 1 were sent, on behalf of the research team,
by the lead pharmacists in the two West London ‘phar-
macists in general practice’ sites. The invitation included
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a direction to e-mail a member of the research team
(GDK) if they wanted to be involved in the study. Once
confirmatory e-mails had been received, the log-in de-
tails for access to the questionnaire were individually e-
mailed (by GDK) directly to potential panellists.
In each subsequent round, GDK directly e-mailed the
new log-in details of the updated questionnaires to those
panellists involved in one of the previous round(s). Two
weeks after the initial invitation, the lead pharmacists
sent a follow-up invitation e-mail to the whole potential
panel encouraging them to take part in the study.
e-Delphi rounds
The study’s endpoint was consensus according to a
preconceived criterion (agreement ≥80%). As literature
reports that three Delphi iterations suffice for achiev-
ing consensus [29, 30], it was decided in advance to
carry out a succession of three e-Delphi rounds in
the current study. To foster the achievement of con-
sensus, each round was different in terms of the
questionnaire’s content and the threshold of agree-
ment was progressively elevated (see Analysis of
quantitative data below). In each round, panellists had
the chance to explain their choice for each item and/
or to provide general comments. Feedback from each
previous round (see Fig. 1 for what it included) was
organised into a PDF document and e-mailed, along-
side log-in details, to panellists. Demographic data
was collected in each round including overall years of
practice as qualified healthcare professional, years of
practice within the general practice environment, re-
gion of practice and roles/duties within general
practice.
Round 1
The questionnaire for this round asked panellists to re-
port the extent to which they agreed that each of the
proposed codes was important to record by using a 5-
point Likert scale (1 = definitely disagree, 2 = probably
disagree, 3 = neither agree nor disagree, 4 = probably
agree, 5 = definitely agree). The questionnaire for this
round can be found as an Additional file (see
Additional file 2).
Round 2
In this round, codes were grouped as per their context
(e.g. codes relating to medication review, monitoring,
patient outcomes etc.). Panellists were asked to charac-
terise each code as ‘useful’ or ‘not useful’. The question-
naire for this round can be found as an Additional file
(see Additional file 3).
Round 3
In this round, codes were grouped similarly to Round 2
and panellists were asked to grade them according to their
importance on a 5-point Likert scale (Very Important,
Important, Moderately Important, Slightly Important, Not
at all). For codes related to patient’s ability to manage
medication, where duplication existed (i.e. multiple codes
for the same meaning), panellists were instead asked to
rank the available options in order of importance (1 =
most important and 6 = least important). The question-
naire for this round can be found as an Additional file (see
Additional file 4).
Analysis of quantitative data
Descriptive statistics were employed to analyse quantita-
tive data. In each round, the percentage of panellists in
each score/ranking option was calculated automatically
by the Online Surveys platform. The threshold of agree-
ment was progressively elevated (51% in Round 1, 70%
in Round 2 and 80% in Round 3). In detail, Round 1
codes in which fewer than 51% of panellists scored 4
(probably agree) and 5 (definitely agree) were removed.
In Round 2, codes not characterised as ‘useful’ by at least
70% of panellists were removed. Final consensus was de-
fined as at least 80% of the panellists in Round 3 scoring
within the ‘importance’ area (i.e. ‘Very Important’ and
‘Important’). Similarly, for the ranking question in
Round 3, consensus was implied if 80% or more of the
panellists identified a certain option as belonging in the
same position of the order of importance (i.e. at least
80% of panellists ranked an option as number 1, number
2 etc.).
Figure 1 summarises the process followed in this
study, including the analysis process for the quantitative
data.
Analysis of qualitative data
Panellists in all Delphi rounds were given an identifier
based on round, for example, Round 1, Panellist 1; Round
1, Panellist 2 etc. Panellists’ commentaries from all rounds
were pooled together (on a hard copy) and analysed the-
matically. The six stages of thematic analysis as described
by Braun and Clark were employed (familiarisation with
data, coding, identifying themes, reviewing themes, defin-
ing themes and writing the report) [31]. In detail, com-
mentaries were coded by GDK (the term ‘code’ or ‘coding’
in this context refers to the coding step of qualitative ana-
lysis [32] rather than to activity codes which formed the
questionnaire items in each Delphi round). Codes were
developed on the margins of the hard copies containing
all commentaries and a single code was ascribed to every
different meaning. Codes were confirmed by the whole re-
search team before developing categories. All different
codes were transferred to a Word® document and sorted
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into potential categories. Each category was highlighted
with a different shading on the Word® document. Categor-
ies were eventually collapsed into themes with associated
sub-themes. Themes were then refined and named col-
lectively by the whole research team.
Results
Panellists
Responses were received from 21 individual panellists:
12 in Round 1, 18 in Round 2 and 16 in Round 3 (nine
panellists followed through from Round 1 to 3). All
panellists were employed in general practice and in-
volved in capturing pharmacy services. Table 2 presents
the demographics of the panellists, aggregated for rea-
sons of anonymity.
Panellists reported a wide scope of practice, such
as: various face-to-face consultation clinics including
medication reviews, elements of diagnostics and per-
forming regular home and care home visits,
medication prescribing and monitoring duties includ-
ing high risk drugs (e.g. immunosuppressants, lithium,
warfarin) and overseeing the repeat prescription ser-
vice; managing the discharge/clinical letter workflow
and medicines reconciliations; education duties (e.g.
training medical students or registrar GPs); consult-
ancy work with healthcare professionals (e.g. medica-
tion queries) and leading multidisciplinary clinical
meetings at a practice or broader level; audits and
service reviews; telephone consultations with patients
for advice on minor ailments and triage; and support-
ing the running of Patient Participation Groups. Phar-
macy technicians, under the supervision of
pharmacists, were involved in most of the above ac-
tivities except for authorising prescriptions.
Qualitative data
Commentaries were sorted into three main themes:
challenges and facilitators; level of detail; and activities
Table 2 Demographics of the e-Delphi expert panel
Years of practice as healthcare
professional
Years of practice within the
general practice environment
Region of practice
Pharmacists (19) 5 to 31 years 1 to 23 years Essex, Greater Manchester, London, Midlands, South Wales
Pharmacy technicians (2) > 10 years < 5 years London
Fig. 1 Process followed in the e-Delphi study of pharmacists’ activity in general practice
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related to funding. These themes gave a better under-
standing of the reasons behind the selection of certain
codes as the most important options and allowed ex-
trapolation to relevant recommendations.
Challenges and facilitators
The panellists discussed several factors that might act as
challenges or facilitators in the process of recording
activities.
With regards to challenges, there was a fear that activ-
ity coding might complicate a pharmacist’s working day
(i.e. an extra daily task) and generate additional time-
requirements.
The use of codes is time consuming. For me, coding
would add complexity to [my] working day. (Round 1,
Panellist 1)
Some panellists claimed that the greater the available
options (e.g. codes differentiating activities to a larger
degree), the more laborious the process of coding would
become.
Coding should not be too onerous as it gets difficult to
maintain that high level of reporting. (Round 2,
Panellist 9)
It was also reported that entering a code might occa-
sionally act as a distractor from focusing on the patient
during consultations.
Having codes to use may mean concentrating to
complete templates rather than actually delving
into patients’ needs and care plans. (Round 1,
Panellist 12)
Memorising codes was another reported challenge.
Hard to see how all these codes will be used in the GP
practice setting as pharmacists would have to
remember them. (Round 1, Panellist 5)
There were concerns that codes are likely to be used
irregularly amongst different pharmacists and/or prac-
tices hence complicating any subsequent data collection.
The data extracted might be limited due to an
irregular use of codes. (Round 1, Panellist 1)
Panellists also mentioned that some codes referred to
tasks not frequently carried out by general practice-
based pharmacists. Examples included synchronising
repeat medications, believed to mainly be a task for ad-
ministrators, and reviewing community pharmacists’
Medicine Use Reviews (MURs), infrequently undertaken
by general practice-based pharmacists. A MUR is a
service offered by community pharmacists in the UK
and involves adherence-focused reviews with patients on
certain medicine groups.
Concerning facilitators, it was suggested that a na-
tional activity coding template would ease the process of
coding. All options would be in the same place and
therefore easily accessible.
It would be extremely useful to develop a national
template with all codes on for easy access. (Round 1,
Panellist 4)
There was, however, a fear that a national template
might not entirely account for local needs that individual
practices and/or pharmacists might experience.
Is there such a thing as one size fits all with regards to
a template or should we create an a la carte menu for
people to pick from? (Round 1, Panellist 12)
The need to create clear definitions for all codes was
also highlighted.
All codes need to be clearly defined. (Round 1,
Panellist 3)
Level of detail
The amount of detail the codes should include was fre-
quently commented upon and conflicting opinions were
present.
For example, there was discussion about medication
review codes and whether or not these should:
 Be more specifically attributed to the person
carrying out the review (e.g. pharmacist, GP).
It’s useful to know as quick glance at the code whether
GP or pharmacist did the medication review. (Round
3, Panellist 7)
The details of the clinician on a code are only relevant
for auditing. For everyday practice, the system will
identify the user as the type of clinician. (Round 2,
Panellist 11)
 Define the exact disease area (e.g. asthma, depression
etc.) for which the review was conducted.
Some disease-specific medication review codes are
helpful especially if pharmacists are working in the
earlier part of their employment as independent
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prescribers and sticking to their scope of practice.
(Round 2, Panellist 9)
A general medication review code encompasses all
conditions. If wanted to, you can see what condition-
medication you are reviewing from notes (and can be
searched on the electronic systems) without need to
code specifically. (Round 2, Panellist 8)
 Indicate the level of the review (i.e. presence or
absence of the patient during a review).
Information is limited without the patient [being]
present [at a medication review], so it’s good to code the
patient’s presence or absence. (Round 3, Panellist 8)
Reviewing medication even without the patient adds
some value so segregating it [patient’s presence] out of
the [general] medication review code is of limited
value. (Round 2, Panellist 9)
Activities related to funding
Panellists emphasised the importance of primarily cod-
ing activities associated with the availability of funding
streams for general practices. They provided characteris-
tic examples of funding-related activities such as the
monitoring of high-risk drugs which was viewed as a
part of commissioned ‘out-of-hospital services’ (i.e.
healthcare services offered by UK non-hospital pro-
viders, such as general practices, that attract NHS fund-
ing). In addition, medication reviews for patients with
certain conditions, such as asthma and diabetes, were
believed to qualify for Quality and Outcomes Framework
(QOF) funding. QOF is a program for English, Welsh
and Northern Irish general practices that incentivises
clinical excellence.
We have a huge array of things to do daily and much
of it relates to practice funding so have to be secure in
doing this. This [e-Delphi] study needs to search
against codes already in use for the purposes of QOF/
‘out-of-hospital services’ etc. to get more accurate data.
(Round 1, Panellist 1)
Codes already used in practice for purposes of getting
funding are useful. (Round 3, Panellist 4)
Activity codes
Of the 81 codes in Round 1, 59 codes made it through
to Round 2 (58 from Round 1 and one added following
panellists’ comments) and 34 codes made it through to
Round 3 (33 from Round 2 and one added following
panellists’ comments). Additional file 1 presents percent-
age agreement for each code in all rounds. Final consen-
sus (in Round 3) was reached on ten codes (see Table 3).
Table 4 presents the Round 3 codes that failed to
achieve final consensus. In addition, there was no clear
hierarchy in ranking for the importance of any of the
following Round 3 codes which were subsequently
discarded: ‘able to manage medication’; ‘drug compliance
good’; ‘unable to manage medication’; ‘difficulty man-
aging medication’; ‘uses medication administration sys-
tem’; and ‘needs assistance with medication regimen
adherence’.
Discussion
Of the ten codes for which consensus was reached, eight
relate to activities and two to patient outcomes. The se-
lected patient outcome codes refer to the presence of
side effects and to the satisfactory understanding of
medications. Panellists did not provide reasons for why
they viewed these two patient outcome codes as import-
ant, however, this might be because these codes are seen
as standard checks for a pharmacist to ensure the pa-
tient’s adherence to medication.
The eight chosen activity codes refer to only three dis-
tinct activities: medication review, monitoring of high-risk
drugs and medicines reconciliation. In contrast, general
practice-based pharmacists across the Dudley Clinical
Commissioning Group (i.e. a UK clinically-led body, part
of the NHS, in charge of designing and commissioning
healthcare services for the local area) were found to code
at least 20 different activities ranging from direct patient
care tasks to duties related to education, quality assurance,
repeat prescribing and waste management [33]. Activity
codes in Dudley, however, were determined exclusively by
the service lead without taking account of any validation
by pharmacists or any external expert input, which our
study has done.
The activities favoured for coding are mainly funding-
related tasks: medication reviews (especially for conditions
Table 3 Codes for which final consensus (agreement ≥80%)
was reached
• Medication review done
• Medication review done by pharmacist
• Asthma medication review
• Chronic Obstructive Pulmonary Disease (COPD) medication review
• Diabetes medication review
• Depression medication review
• High-risk drug monitoring
• Medicines reconciliation post-discharge with notes
• Has shown side effects from medication
• Patient understands why taking all medication
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viewed by panellists as the top priorities in QOF: asthma,
COPD, diabetes and depression) along with the monitor-
ing of high-risk drugs which was viewed by panellists as a
priority in ‘out-of-hospital services’. The fact that one of
the national KPIs accounts for the ability to meet QOF
targets might have arguably influenced panellists’ choice
of codes. These results support the finding that there is in-
creasing engagement of UK general practice-based phar-
macists with incentive programs related to funding
acquisition for their employer practices [34]. Panellists,
however, provided no comments on why they chose medi-
cines reconciliation (not viewed as funding-related) as an
activity to code.
As shown in Additional file 1, the majority of codes that
made it through to Round 3 had also good percentage
agreement in Rounds 2 and 1. Some codes, however, with
high percentage agreement in Round 2 did not get final
consensus in Round 3. For instance, the ‘no drug side ef-
fect reported’ code did not maintain high percentage
agreement in contrast to its opposite ‘has shown side ef-
fects from medication’ code. This could have been because
it is more important for pharmacists to record the pres-
ence rather than the absence of side effects, for example,
to alert the rest of the general practice-based team. Codes
describing the patient’s ability to manage medications
were also discarded in Round 3, perhaps because they
were not deemed as direct measures of a pharmacist’s ac-
tivity (these codes describe patient behaviours). It is also
worth noting that panellists finally selected a medicines
reconciliation code pointing out the availability of patient
notes rather than the generic ‘medicines reconciliation
performed’. This choice makes sense, terminology-wise,
because medicines reconciliation cannot properly be done
without access to patient notes [35]. Panellists rejected
codes describing medication reviews for anticoagulants
and antipsychotics, despite the fact that one of the KPIs
requires general practice-based pharmacists to reduce
antipsychotic prescribing. These codes were possibly ex-
cluded because patients on antipsychotics or anticoagu-
lants would be under hospital or specialist care.
General practice-based pharmacists were against having
to deal with a large number of codes because they would
be onerous, provide more detail than necessary and be less
likely to have universal uptake. A few, higher-order codes
were preferred instead. For instance, panellists did not se-
lect codes describing specific actions taken during a medi-
cation review (such as altering medication, ascertaining
adherence and offering advice about treatment), most
likely because these could be covered and implied under
the higher-order ‘medication review done’ code. Probably
for the same reason of avoiding large numbers of codes,
panellists excluded codes indicating the level of a review
and codes believed to describe rare tasks for general prac-
tice-based pharmacists such as synchronising repeat medi-
cations and reviewing community pharmacists’ MURs.
Although communication with community pharmacists
was recognised during the initial focus groups as an im-
portant element of general practice-based pharmacist’s
role [23], panellists did not consider it important enough
to code how often it happens. The ‘contact with local
community pharmacy’ code was rejected potentially be-
cause interactions between general practice-based and
community pharmacists are extremely frequent [34] and
using codes would have made coding quite time
consuming.
To dispel fears about the negative impact that the use of
codes could have on day-to-day workflow, additional sim-
plification of the activity coding process could be benefi-
cial. For example, an Australian public hospital employed
barcode technology to facilitate capture of pharmacists’
activities [36]. Technology can ease reference to codes and
accelerate their entry into clinical computer systems thus
making activity coding a smoother process for general
practice-based pharmacists.
Implications
This study has shown consensus on a number of activity
(and patient outcome) codes. Clear definitions of codes
along with policies on their use need to be created (e.g.
explanations of terminology, instances or prerequisites
for entering each code) to encourage an unvarying appli-
cation of codes and hence facilitate any subsequent data
collection.
Strengths and limitations
This is the first study that has followed an acknowledged
consensus method to determine general practice-based
pharmacists’ preferences concerning activity coding. As
Table 4 Codes in Round 3 that failed to achieve final consensus
(categorised by percentage agreement*)
Agreement
70–80%
• Antipsychotic medication review
• Polypharmacy medication review
• Medication changed
• New medication added
• Medicines reconciliation performed
Agreement
60–70%
• Medicines adherence checked
• Advice about drug treatment
• Advice about side effects of drug treatment
• Medication review without patient
• Anticoagulation medication review
• Drug changed to cost effective alternative
• Medication stopped
• Medication stopped-side effect
• Medication error
Agreement
50–60%
• No drug side effect reported
• Synchronisation of repeat medication
• Contact with the local community pharmacy
• Medicine Use Review (MUR) done by community
pharmacist
*Percentage agreement indicates how many panellists identified a code as
‘Very Important’ and ‘Important’
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the Delphi method requires, the panel used in the current
study included some of the key experts on the topic who
have been following the evolution of UK general practice-
based pharmacists’ roles for many years. Consequently,
findings reflect real needs/requirements concerning
capturing pharmacists’ impact in general practice and,
additionally, account for diverse levels of experience
(people relatively new in general practice were also repre-
sented in the study) as well as different geographical areas
of practice. The study explored the views of the whole
pharmacy team in general practice including pharmacy
technicians who are increasingly contributing to general
practice-based activities [37].
As it was an entirely UK-based study, findings might
not be generalisable to other countries due to possible dif-
ferences between healthcare systems. Individual elements,
however, will still be useful wherever attempts are being
made to implement and justify general practice-based
pharmacists’ services. For example, aspects of the findings
might be useful to Australia, Canada and New Zealand
which all have formal programs for integrating and testing
pharmacists’ services in general practice [38–40]. The ori-
ginal list of activity codes was mainly based on only one
clinical computer system and there might be additional
codes present on other systems. Panellists, however, had
the chance throughout the Delphi study (and in the initial
focus groups before the actual Delphi rounds) to suggest
any other activities of importance to capture. Therefore, it
is anticipated that the study has identified the important
activities for recording general practice-based pharmacists’
impact regardless of the clinical computer system used.
Conclusions
This study followed a formal consensus technique to offer
insight into needs and preferences of general practice-
based pharmacists with regards to activity coding. Final
consensus was reached for ten codes with a notable pref-
erence for codes required for obtaining general practice
funding. These findings will be useful for general practice-
based pharmacists wanting to align their activity coding
practices with options widely recognised as useful. These
findings will also inform policy that attempts to shape ac-
tivity coding for general practice-based pharmacists by
considering pharmacists’ actual needs and preferences.
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